Save time and money with
Med Tech Market Research

MedTech Business intelligence
supplied by GlobalData


World Pharmaceutical and Biopharmaceutical Market 2010-2015
(Pipeline Analysis of the Top 50 Companies)

Publication Date: July 2010
Publisher: Kalorama Information
Pages: 230 

What Will The Pharmaceutical Market Look Like in the Next Five Years?

This research undertaking is the result of a detailed analysis of the late stage R&D pipeline of the 50 top companies in pharmaceuticals, the companies that produce the lion's share of revenues.

While the report looks at the entire pipeline to 2015, a key focus of the report is the increasing role of biopharmaceutical products. The growing interest in biotechnology development has transitioned the pharmaceutical industry to biopharmaceuticals in less than a decade.

 Companies such as Pfizer, Merck and Novartis have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

Companies such as Amgen and Genzyme, which specialize in biotechnology, are now competing with a growing number of companies and the lines between pharmaceutical and biotechnology specialty companies are becoming more blended; which is a trend expected to continue to grow.

This Kalorama Information market research report, The World Pharmaceutical and Biopharmaceutical Market, 2010-2015 (Pipeline Analysis of the Top 50 Companies) captures these trends, extracting sales for all pharmaceutical and biopharmaceutical products (excluding prophylactic vaccines) and providing estimates and forecasts of the world biopharma market.

Biopharma and pharma: the line becomes blurred

The line between pharmaceutical companies and biopharmaceutical companies is blurred to the point of no longer being a distinct. Among the top companies in biopharmaceuticals are, not surprisingly, the same names that have dominated pharmaceuticals for years - Pfizer, Merck and Novartis.

These companies have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.

 Specialist companies such as Amgen and Genzyme, now competing with a growing number of companies. The result of all interest in biological solutions to major diseases? In creased activity in the research and development departments of major pharmaceutical companies in recent years, activity that we believe will have near-term market impact.

Biopharmaceuticals are defined as any substance produced by natural organisms or recombinant techniques consisting of proteins and other products derived from living organisms for the treatment or management of diseases or injuries. Biopharmaceuticals are created through fermentation, recombinant DNA technology, and other bioprocesses.

The complex nature of biopharmaceuticals and the growing interest in development of these products has resulted in a flood of new issues affecting the already complicated healthcare market. There are a number of issues and trends which are experienced by the healthcare industry as a whole and others which are unique to biopharmaceuticals, their development and commercialization.

Key issues and trends in the industry

Issues and Trends discussed in this report include:

  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • Biosimilar Development
  • Aging Populations
  • Mergers, Acquisitions, and Collaborations
  • Contributors to R&D Success
  • R&D Spending Trends
  • The Role of Contract Research Organizations
  • Sustainability in a Changing Pharmaceutical Industry
Also, despite an in-depth interview process and complete review of company financials, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical and biopharmaceutical sales are not discussed.

In this comprehensive look a the pipeline of major companies, Kalorama Information presents an accurate picture of the marketplace today, including:

  • Market Estimates by Major Drug Category, including:
    • Cardiovascular/Blood
    • Neurotherapeutics
    • Infection
    • Oncology
    • Respiratory/Inflammatory
    • Gastrointestinal
    • Other
  • Discussion of Marketplace Trends
  • Pipeline Analysis of Major Pharmacos
  • Detailed Company Profiles
  • Comparison of Market at Current Growth Versus Impact of Late-Stage Products
  • Biopharmaceutical Market Breakdown
  • Best-Selling Biopharmaceutical Products
  • Regulatory Activity and Market Impact

Kalorama Information's market research into this topic is based on review of government filings and company literature, but also interviews with executives and experts, and the perspective of an analyst who has authored scores of reports in this industry.

Late Stage Product Development of the Top 50 Companies

50 top companies make up over 90% of the world biopharmaceutical market; The top three companies have nearly a quarter of global sales in 2009.

The top 50 companies discussed in this report include:

  • Abbott
  • Actelion
  • Alcon, Inc.
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Baxter International
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Cephalon
  • Chugai Pharmaceutical
  • CSL
  • Daiichi Sankyo
  • Dainippon
  • Eisai
  • Eli Lilly & Co.
  • Endo
  • Forest
  • Genzyme
  • Gilead Sciences
  • GlaxoSmithKline
  • Hospira
  • Johnson & Johnson
  • Lundbeck
  • Menarini
  • Merck
  • Merck KGaA
  • Mitsubishi Tanabe Pharma
  • Mylan
  • Novartis
  • Novo Nordisk
  • Nycomed
  • Ono Pharmaceutical Co.
  • Otsuka Pharmaceutical
  • Pfizer
  • Procter & Gamble
  • Purdue Pharma
  • Roche
  • Sanofi-Aventis
  • Servier
  • Shionogi
  • Shire
  • Takeda
  • TEVA
  • UCB
  • Watson

 

To top

 
 

To top